Literature DB >> 11361209

Arthritis, Rheumatism and Aging Medical Information System Post-Marketing Surveillance Program.

G Singh1.   

Abstract

The Arthritis, Rheumatism, and Aging Post-Marketing Surveillance Program (ARAMIS-PMS) is a collection of multicenter, prospective, noninterventional, observational longitudinal studies of patients with rheumatic diseases. The ARAMIS-PMS program aims to study patients in normal clinical setting to evaluate the real-life effectiveness, toxicity, and cost effectiveness of various medications used to treat rheumatic diseases.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11361209

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  3 in total

Review 1.  Cardiovascular effects of approved drugs for rheumatoid arthritis.

Authors:  Fabiola Atzeni; Javier Rodríguez-Carrio; Călin D Popa; Michael T Nurmohamed; Gabriella Szűcs; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2021-04-08       Impact factor: 20.543

2.  Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank.

Authors:  Esi Morgan DeWitt; Li Lin; Henry A Glick; Kevin J Anstrom; Kevin A Schulman; Shelby D Reed
Journal:  Clin Ther       Date:  2009-08       Impact factor: 3.393

3.  Percentile benchmarks in patients with rheumatoid arthritis: Health Assessment Questionnaire as a quality indicator (QI).

Authors:  Eswar Krishnan; Peter Tugwell; James F Fries
Journal:  Arthritis Res Ther       Date:  2004-09-14       Impact factor: 5.156
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.